Biocon Limited Completes QIP, Allots 11.26 Crore Shares Worth ₹4,150 Crore
Biocon Limited has completed its Qualified Institutions Placement (QIP), allotting 11.26 crore equity shares at ₹368.35 each. The company raised ₹4,150 crore (₹41,500 million) through this issuance. The trading window for securities will reopen on January 17, 2026.
The QIP raised a substantial amount of capital (₹4,150 crore), which can significantly impact the company's financial structure, funding for future projects, and overall market valuation.
The successful completion of a QIP and raising a significant amount of capital is a positive development for the company, indicating investor confidence and providing funds for growth or other corporate purposes.
Biocon Limited announced the successful completion of its Qualified Institutions Placement (QIP) issue, allotting 11,26,64,585 equity shares of face value ₹5 each. The allotment was approved by the Fund Raising Committee at a meeting held on January 14, 2026. The issue price was fixed at ₹368.35 per equity share, including a premium of ₹363.35 per equity share.
The total amount raised through this QIP amounts to ₹41,500 million (₹4,150 crore). The Issue was open from January 12, 2026, to January 14, 2026.
Following the allotment, Biocon's paid-up equity share capital has increased to ₹8,10,45,38,865, comprising 1,62,09,07,773 equity shares. The company also informed that the trading window for dealing in its securities, which was closed for the QIP, will reopen on January 17, 2026.
The announcement also included a list of allottees who received more than 5% of the equity shares offered in the issue, with SBI Contra Fund and ICICI Prudential Value Fund being significant allottees.
What to do with a filing like this
Biocon Limited filed this with the NSE as a statutory disclosure, categorised under equity fundraising. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Biocon Limited. Read the original for the full detail.